GOLD guidance glistens for Novartis and Vectura
New guidance which recommends the use of certain inhalers over others in chronic obstructive pulmonary disease (COPD) sent the share prices of the companies which market the products involved in different directions.
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 report recommends the use of inhalers that do not use steroids, advice which could hurt the big-selling AdvairDiskus (fluticasone propionate and salmeterol) product sold by UK pharma major GlaxoSmithKline (LSE: GSK).
Companies seeking to sell generic versions of AdvairDiskus were also affected, in particular Jordan-headquartered Hikma Pharmaceuticals (LSE: HIK), shares in which dropped by 4% on Thursday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze